Alabama's Right-to-Try statute allows investigational adult stem cell therapy for severe chronic and terminal disease.
Statute
AL SB 16, Ala. Code § 22-5D-1
Effective
SB 16 (2017), § 22-5D-1 (2024)
Alabama law allows investigational adult stem cell therapies for patients with severe chronic or terminal diseases after exhausting other treatment options, with informed consent and IRB oversight. The 2024 Right-to-Try update notably does not exclude stem cells.
The requirements below are set by AL SB 16, Ala. Code § 22-5D-1. Compliance is the responsibility of each individual treating physician under their state license.
Statutory compliance does not equal FDA approval. The procedures discussed are investigational and have not been approved by the US Food and Drug Administration.
Alabama has enacted AL SB 16, Ala. Code § 22-5D-1, which sets out specific conditions under which a state-licensed physician may practice in this area. The procedures discussed here are investigational and have not been approved by the US Food and Drug Administration.
No. Adults may travel to Alabama from any US state for an in-person consultation with a network physician. Whether any procedure is appropriate is a clinical decision determined by the treating physician.
Cost depends on the indication, the cell product, and the treating physician. Each physician sets their own pricing and provides a written estimate. Select Stem Cell does not collect medical fees on behalf of physicians.
Yes. Alabama law requires the treating physician to provide written disclosure of investigational status and obtain informed consent prior to any procedure.
Continue Reading
We use cookies
We use strictly necessary cookies to make this site work, and (with your permission) functional and analytics cookies to improve your experience. We do not use marketing or behavioral-advertising cookies. Read our Cookie Policy.